BioMarins SWOT analysis rare disease leaders stock faces growth hurdles
ASND Stock | USD 139.50 3.12 2.29% |
About 59% of all Ascendis Pharma's shareholders are looking to take a long position. The analysis of the overall investor sentiment regarding Ascendis Pharma AS suggests that some traders are interested. The current market sentiment, together with Ascendis Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Ascendis Pharma AS stock news signals to limit their universe of possible portfolio assets.
Ascendis |
BioMarins SWOT analysis rare disease leaders stock faces growth hurdles
Read at investing.com
Ascendis Pharma Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Ascendis Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ascendis Pharma Fundamental Analysis
We analyze Ascendis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascendis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascendis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Ascendis Pharma is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Ascendis Pharma AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ascendis Pharma stock to make a market-neutral strategy. Peer analysis of Ascendis Pharma could also be used in its relative valuation, which is a method of valuing Ascendis Pharma by comparing valuation metrics with similar companies.
Peers
Ascendis Pharma Related Equities
ETNB | 89bio | 12.94 | ||||
BGNE | BeiGene | 1.26 | ||||
ACLX | Arcellx | 1.11 | ||||
UTHR | United Therapeutics | 0.77 | ||||
NUVL | Nuvalent | 0.39 | ||||
APLS | Apellis Pharmaceuticals | 0.12 | ||||
STOK | Stoke Therapeutics | 0.34 | ||||
PLRX | Pliant Therapeutics | 0.68 | ||||
AMLX | Amylyx Pharmaceuticals | 0.99 | ||||
DAWN | Day One | 1.02 | ||||
BPMC | Blueprint Medicines | 1.16 | ||||
MDGL | Madrigal Pharmaceuticals | 1.17 | ||||
REPL | Replimune | 1.20 | ||||
CRNX | Crinetics Pharmaceuticals | 1.68 | ||||
VTYX | Ventyx Biosciences | 1.75 | ||||
AKRO | Akero Therapeutics | 3.14 |
Complementary Tools for Ascendis Stock analysis
When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Money Managers Screen money managers from public funds and ETFs managed around the world |